Chamomile
Phase 3Small molecule
Chamomile is one of 82 small molecule programs targeting Oral Lichen Planus. It is currently in Phase 3.
4
Indications
4
Total Trials
0
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
165 competitors in Anxiety
#DrugCompanyPhaseTrials
1Duloxetine Hydrochloride
Eli LillyPhase 3
Chamomile
HHams Hamed Abdelrahman
Phase 3
Centanafadine
OtsukaPhase 3
Yohimbine Hydrochloride
UUnknown Sponsor
Phase 3
Celexa
AbbViePreclinical
Spravato
WWim Janssens
Preclinical
Campral
FForest Laboratories
Preclinical
Anerem
AAcacia Pharma Ltd
Preclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Andriol
AAuxilium
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oral Mucositis1 trial
Low Level Diode Laser Versus Topical Chamomile in Management of Chemotherapy Induced Oral Mucositis
Unknown status·—·Phase 2·NCT06214273·45 enrolled
Oral Lichen Planus1 trial
Evaluation of Topical Chamomile Versus Topical Triamcinolone Acetonide in Management of Oral Lichen Planus
Unknown status·—·Phase 1·NCT03793634·37 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Chamomile. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- HHams Hamed Abdelrahman